Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | PTGES | O14684 | 8/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184510 | 0.85 | BACE1 (0.40) | CA2PTGESGRIN2DGRIN3BGRIN1 | |
| SCHEMBL183970 | 0.76 | HDAC1 (0.36) | CA2PTGESGRIN2DGRIN3BGRIN1 | |
| SCHEMBL15859356 | 0.73 | CA2 (0.49) | CA2BCHEBACE1 | |
| SCHEMBL185030 | 0.70 | ACLY (0.56) | CA2 | |
| SCHEMBL1500516 | 0.69 | HDAC1 (0.40) | CA2 | |
| SCHEMBL6566661 | 0.68 | LOXL2 (0.59) | CA2 | |
| SCHEMBL18756348 | 0.66 | CA2 (0.59) | CA2 | |
| SCHEMBL18756484 | 0.66 | CA2 (0.44) | CA2BCHEBACE1 | |
| SCHEMBL15771123 | 0.66 | LMNA (0.59) | CA2 | |
| SCHEMBL21799981 | 0.66 | CA2 (0.47) | CA2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |